Statin gyógyszerszedési gyakorlat myocardialis infarctus után Magyarországon

Abstract

Abstract: Introduction: Statin therapy has proven to be one cornerstone for prevention and treatment of cardiovascular disease, but the clinical application is suboptimal. Adherence to statin therapy in Hungary in primary prevention is very low, but not known in patients with myocardial infarction. Aim: This study was designed to determine the statin and ezetimib adherence after myocardial infarction in respect of total mortality. Method: A retrospective study was carried out based on the National Health Insurance database between 2013–2015. Adherence was measured after minimum 6 months therapy and at least 80% statin prescription. Results: Total mortality rate after myocardial infarction was 12,7% after 6 months, 16,2% after one year and 21,7% after two years. Statin adherence after myocardial infarction reached 70%. The adherence was higher among patients with high dose than the modest dose statin therapy. Adherence with the combination of statin-ezetimibe therapy was lower than with statin monotherapy. Adherence with modest intensity statin-ezetimibe combination was only 40%. High intensity statin-ezetimibe combination resulted 66% adherence. Conclusions: The myocardial infarction mortality remain high in the first two years. Adherence to high or modest dose statin is better than in primary prevention. The patient number on statin-ezetimibe combination is very low, which means that lot of patients are not on the target level of LDL cholesterin. Orv. Hetil., 2017, 158(12), 443–446.